AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT NOVEMBER 1, 2013Manufacturing Services Agreement • January 26th, 2015 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • Ontario
This Amendment No. 1 is intended to modify the MANUFACTURING SERVICES AGREEMENT (the “Agreement”) dated March 12, 2010 by and between OREXIGEN THERAPEUTICS, INC., a corporation existing under the laws of the State of Delaware (“Client”), and Patheon Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, and Patheon Inc., a corporation existing under the laws of Canada (collectively, “Patheon”). All capitalized terms used herein and not otherwise defined will have the meanings assigned to such terms in the Agreement.
AMENDED AND RESTATED MASTER AGREEMENT FOR PHARMACEUTICAL DEVELOPMENT SERVICESMaster Agreement for Pharmaceutical Development Services • January 26th, 2015 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • New York
Manufacturing Services Agreement March 12, 2010Manufacturing Services Agreement • January 26th, 2015 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:
